UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 15, 2016

 

 

TetraLogic Pharmaceuticals Corporation

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

001-36208

 

42-1604756

(State or Other Jurisdiction
of Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

343 Phoenixville Pike
Malvern, PA 19355
(610) 889-9900

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal
Executive
Offices)

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 15, 2016, TetraLogic Pharmaceuticals Corporation (the “Company”) held its Annual Meeting of Stockholders.  The following proposals were submitted by the Company’s Board of Directors to a vote of the Company’s stockholders and the final results of the voting on each proposal are noted below.

 

Proposal 1 — Election of Directors

 

The stockholders elected the following individuals to serve as Class III directors for three-year terms until the 2019 annual meeting of stockholders and until each director’s successor is elected and qualified:

 

Name

 

Votes For

 

Votes Withheld

 

Broker
Non-Votes

 

J. Kevin Buchi

 

5,742,341

 

125,647

 

9,052,246

 

Paul J. Schmitt

 

5,721,032

 

146,956

 

9,052,246

 

 

Proposal 2 — Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016

 

The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016 as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

14,616,487

 

161,928

 

141,819

 

—

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 15, 2016

TetraLogic Pharmaceuticals Corporation

 

 

 

 

By:

/s/ Richard L. Sherman

 

 

Name: Richard L. Sherman

 

 

Title: Senior Vice President, Strategic Transactions, General Counsel and Secretary

 

3

TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 TetraLogic Pharmaceuticals (CE) 차트를 더 보려면 여기를 클릭.
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 TetraLogic Pharmaceuticals (CE) 차트를 더 보려면 여기를 클릭.